What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call
Aquestive Therapeutics reported Q3 revenue of $7.6M, down from $12.8M YoY, due to Suboxone order fluctuations. The company discussed payer negotiations for Anaphylm, a potential differentiator in epinephrine treatment. Aquestive also announced a licensing deal for Libervant with Eton Pharmaceuticals, receiving a $10M upfront payment. The company expects to end 2026 with over $70M in cash and maintained its 2026 revenue outlook of $46M-$50M.
How this was made

The 30-second read
Why it matters
The earnings miss may trigger short‑covering and price declines, but the licensing deal and cash runway could mitigate downside.
Market read
Micro‑cap biotech earnings with a revenue decline and loss, offset by a licensing upfront payment and cash runway.
What to watch
Potential upside from upcoming Anaphylm approval and AdrenaVerse pipeline not reflected in current price.
Background
Aquestive Therapeutics (NASDAQ:AQST) is a specialty pharma focused on oral film delivery, with products Libervant and Exservan already on market.
Ticker impact
Q3 earnings release shows revenue down 40% YoY, net loss widening and guidance unchanged, plus a $10M upfront licensing payment.
likely downward pressure as investors digest lower revenue and higher loss.
The company reported a sharp revenue decline, a larger net loss, and only modest cash balance, which typically triggers sell‑offs in micro‑cap pharma stocks.
Market effects
Highlights continued pressure on specialty pharma micro‑caps with pending FDA reviews.
Limited to U.S. biotech investors; no broader market effect.
Minimal global impact beyond niche biotech community.
Counterpoint
The $10M upfront payment and potential $75M strategic funding could provide runway, suggesting upside if the pipeline de‑risked.
Key entities
- partnerEton Pharmaceuticals
Exclusive U.S. commercialization rights holder for Libervant.
- lenderOaktree
Provider of a term‑loan facility referenced in the guidance.


